Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study

Table 2 The risk of hospitalization of SGLT-2i treated patients for heart failure according to follow-up period compared with DPP-4i treated patients

Days after the drug initiation	Events	HR	lower CI	upper CI	p value
Total patients (N = 118,958)
30 days	256	0.74	0.58	0.95	0.02
90 days	456	0.75	0.62	0.90	0.002
180 days	617	0.71	0.61	0.84	< 0.001
1 year	818	0.73	0.63	0.84	< 0.001
3 years	1025	0.66	0.58	0.75	< 0.001
Patients with underlying cardiovascular disease (N = 22,376)
30 days	117	0.62	0.43	0.91	0.01
90 days	220	0.73	0.5666	0.95	0.02
180 days	296	0.69	0.55	0.88	< 0.001
1 year	400	0.69	0.56	0.84	< 0.001
3 years	492	0.66	0.58	0.78	< 0.001
Patients without underlying cardiovascular disease (N = 96,580)
30 days	123	1.09	0.76	1.55	0.65
90 days	218	0.89	0.68	1.16	0.39
180 days	298	0.83	0.66	1.05	0.12
1 year	403	0.83	0.68	0.84	0.06
3 years	502	0.76	0.63	0.95	0.003

ISSN: 1475-2840